

Andrew Kung

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6745950/andrew-kung-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

296
papers

34,447
citations

90
h-index

184
g-index

345
ext. papers

38,326
ext. citations

9.9
avg, IF

6.52
L-index

#	Paper	IF	Citations
296	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.. <i>Nature Communications</i> , 2022 , 13, 2485	17.4	4
295	Bromodomain 4 inhibition leads to MYCN downregulation in Wilms tumor. <i>Pediatric Blood and Cancer</i> , 2021 , e29401	3	2
294	Comprehensive Molecular Profiling of Desmoplastic Small Round Cell Tumor. <i>Molecular Cancer Research</i> , 2021 , 19, 1146-1155	6.6	3
293	An expanded universe of cancer targets. <i>Cell</i> , 2021 , 184, 1142-1155	56.2	38
292	STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma. <i>Cancer Cell</i> , 2021 , 39, 827-844.e10	24.3	7
291	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. <i>Nature Cancer</i> , 2021 , 2, 357-365	15.4	23
290	Stepwise Strategic Mitigation Planning in a Pediatric Oncology Center During the COVID-19 Pandemic. <i>Journal of Pediatric Oncology Nursing</i> , 2021 , 38, 176-184	2	
289	Translational Strategies for Repotrectinib in Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 2189-2197	6.1	0
288	Important Concerns Over SARS-CoV-2 Infection in Children With Cancer-Reply. <i>JAMA Oncology</i> , 2020 , 6, 1980	13.4	2
287	COVID-19 in Children With Cancer in New York City. <i>JAMA Oncology</i> , 2020 , 6, 1459-1460	13.4	107
286	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. <i>Cancer</i> , 2020 , 126, 3114-3121	6.4	11
285	Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. <i>Blood</i> , 2020 , 136, 30-31	2.2	
284	Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF- κ B Pathway in Preclinical Models of Pediatric High-Grade Glioma. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 540-551	6.1	7
283	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020 , 39, 2305-2327	9.2	12
282	Summary of COVID-19 clinical practice adjustments across select institutions. <i>Pediatric Blood and Cancer</i> , 2020 , 67, e28411	3	4
281	Isabl Platform, a digital biobank for processing multimodal patient data. <i>BMC Bioinformatics</i> , 2020 , 21, 549	3.6	4
280	Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel Fusion-Driven Cancer. <i>Cancer Discovery</i> , 2019 , 9, 605-616	24.4	8

279	High-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma. <i>Clinical Cancer Research</i> , 2019 , 25, 4552-4566	12.9	18
278	Adipocytes sensitize melanoma cells to environmental TGF- β s by repressing the expression of miR-211. <i>Science Signaling</i> , 2019 , 12,	8.8	13
277	Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. <i>Blood</i> , 2019 , 134, 2361-2368	2.2	91
276	Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2018 , 10,	17.5	50
275	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, 2144-2149	11.5	45
274	Germline mutations in children and adults with cancer. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	20
273	A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. <i>Nature Genetics</i> , 2018 , 50, 979-989	36.3	90
272	Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10552-10552	2.2	1
271	Local drug activation technology to make cytotoxics safer for localized solid tumors.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 12082-12082	2.2	
270	Recurrent EML4-NTRK3 fusions in infantile fibrosarcoma and congenital mesoblastic nephroma suggest a revised testing strategy. <i>Modern Pathology</i> , 2018 , 31, 463-473	9.8	86
269	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. <i>Journal of Experimental Medicine</i> , 2018 , 215, 197-216	16.6	16
268	Whole-Genome and Whole-Exome Sequencing in Pediatric Oncology: An Assessment of Parent and Young Adult Patient Knowledge, Attitudes, and Expectations. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	3
267	A recurrent novel fusion identifies a new subtype of high-grade spindle cell sarcoma. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	20
266	BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1 β activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018 , 115, E9600-E9609	11.5	14
265	Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2017 , 23, 1012-1024	12.9	65
264	Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1779-1790	6.1	31
263	Image-guided transplantation of single cells in the bone marrow of live animals. <i>Scientific Reports</i> , 2017 , 7, 3875	4.9	10
262	A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. <i>Journal of Physical Education and Sports Management</i> , 2017 , 3, a001396	2.8	18

261	Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	23
260	HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. <i>Oncotarget</i> , 2017 , 8, 80109-80123	3.3	18
259	Successful Targeted Therapy of Refractory Pediatric Fusion-Positive Secretory Breast Carcinoma. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	21
258	PI3K γ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 2069-2082	6.1	4
257	Pediatric Sarcoma Data Forms a Unique Cluster Measured via the Earth Mover's Distance. <i>Scientific Reports</i> , 2017 , 7, 7035	4.9	7
256	Germline mutations detected in pediatric sequencing studies impact parents' evaluation and care. <i>Journal of Physical Education and Sports Management</i> , 2017 , 3,	2.8	13
255	Precision Medicine in Children and Young Adults with Hematologic Malignancies and Blood Disorders: The Columbia University Experience. <i>Frontiers in Pediatrics</i> , 2017 , 5, 265	3.4	17
254	Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. <i>Leukemia</i> , 2016 , 30, 190-9	10.7	54
253	Bacterial bloodstream infections in pediatric allogeneic hematopoietic stem cell recipients before and after implementation of a central line-associated bloodstream infection protocol: A single-center experience. <i>American Journal of Infection Control</i> , 2016 , 44, 1650-1655	3.8	19
252	A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. <i>Genome Medicine</i> , 2016 , 8, 116	14.4	14
251	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2016 , 213, 1285-306	16.6	85
250	Survival Impact of Early Post-Transplant Toxicities in Pediatric and Adolescent Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Malignant and Nonmalignant Diseases: Recognizing Risks and Optimizing Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1646-1653	4.7	9
249	Risk Factors and Utility of a Risk-Based Algorithm for Monitoring Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections in Pediatric Recipients after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1646-1653	4.7	31
248	Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 957-61	4.7	10
247	High-throughput identification of genotype-specific cancer vulnerabilities in mixtures of barcoded tumor cell lines. <i>Nature Biotechnology</i> , 2016 , 34, 419-23	44.5	127
246	Molecular Profiling of High-Risk Pediatric Acute Myeloid Leukemia. <i>Blood</i> , 2016 , 128, 5250-5250	2.2	0
245	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2077-2077	2.2	2
244	Evaluating genetic and genomic sequencing knowledge from parents and young adult cancer survivors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1579-1579	2.2	0

243	Targeting MTHFD2 in acute myeloid leukemia. <i>Journal of Cell Biology</i> , 2016 , 214, 2141-2151	7.3	
242	Leukemia-Specific Delivery of Mutant NOTCH1 Targeted Therapy. <i>Blood</i> , 2016 , 128, 889-889	2.2	
241	The 2-oxoglutarate analog 3-oxoglutarate decreases normoxic hypoxia-inducible factor-1 α in cancer cells, induces cell death, and reduces tumor xenograft growth. <i>Hypoxia (Auckland, NZ)</i> , 2016 , 4, 15-27	2.1	6
240	Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations. <i>Genome Medicine</i> , 2016 , 8, 133	14.4	95
239	The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. <i>Cancer Cell</i> , 2016 , 29, 574-586	24.3	154
238	Allogeneic Hematopoietic Cell Transplantation for Children with Sickle Cell Disease Is Beneficial and Cost-Effective: A Single-Center Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1258-1265	4.7	39
237	Acute gastrointestinal graft-vs-host disease is associated with increased enteric bacterial bloodstream infection density in pediatric allogeneic hematopoietic cell transplant recipients. <i>Clinical Infectious Diseases</i> , 2015 , 61, 350-7	11.6	27
236	Examining the utility of patient-derived xenograft mouse models. <i>Nature Reviews Cancer</i> , 2015 , 15, 311-313	6.3	246
235	¹⁸ F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models. <i>Cold Spring Harbor Protocols</i> , 2015 , 2015, 176-9	1.2	4
234	Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach. <i>Blood</i> , 2015 , 125, 3133-43	2.2	18
233	Noninvasive imaging of tumor burden and molecular pathways in mouse models of cancer. <i>Cold Spring Harbor Protocols</i> , 2015 , 2015, 135-44	1.2	24
232	Mediator kinase inhibition further activates super-enhancer-associated genes in AML. <i>Nature</i> , 2015 , 526, 273-276	50.4	226
231	Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia. <i>Nature Medicine</i> , 2015 , 21, 1182-9	50.5	139
230	Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2015 , 168, 230-8	4.5	15
229	Complete hematologic response of early T-cell progenitor acute lymphoblastic leukemia to the secretase inhibitor BMS-906024: genetic and epigenetic findings in an outlier case. <i>Journal of Physical Education and Sports Management</i> , 2015 , 1, a000539	2.8	40
228	In vivo imaging of endogenous enzyme activities using luminescent 1,2-dioxetane compounds. <i>Journal of Biomedical Science</i> , 2015 , 22, 45	13.3	16
227	Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. <i>Neuro-Oncology</i> , 2015 , 17, 697-707	1	34
226	Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2015 , 1, a000471	2.8	32

225	Human herpesvirus-6 viremia is not associated with poor clinical outcomes in children following allogeneic hematopoietic cell transplantation. <i>Pediatric Transplantation</i> , 2015 , 19, 737-44	1.8	9
224	Overcoming challenges to meaningful informed consent for whole genome sequencing in pediatric cancer research. <i>Pediatric Blood and Cancer</i> , 2015 , 62, 1374-80	3	20
223	Inhibition of inflammatory arthritis using fullerene nanomaterials. <i>PLoS ONE</i> , 2015 , 10, e0126290	3.7	32
222	Quantitative bioluminescence imaging of mouse tumor models. <i>Cold Spring Harbor Protocols</i> , 2015 , 2015, pdb.prot078261	1.2	5
221	Preclinical magnetic resonance imaging in mouse cancer models. <i>Cold Spring Harbor Protocols</i> , 2015 , 2015, pdb.prot078253	1.2	
220	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, 232-7	11.5	112
219	Efficacy of tacrolimus/mycophenolate mofetil as acute graft-versus-host disease prophylaxis and the impact of subtherapeutic tacrolimus levels in children after matched sibling donor allogeneic hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 496-502	4.7	14
218	Selective Inhibition of HDAC1 and HDAC2 as a Potential Therapeutic Option for B-ALL. <i>Clinical Cancer Research</i> , 2015 , 21, 2348-58	12.9	42
217	Proxe: A Public Repository of Xenografts to Facilitate Studies of Biology and Expedite Preclinical Drug Development in Leukemia and Lymphoma. <i>Blood</i> , 2015 , 126, 3252-3252	2.2	1
216	A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2044-2044	2.2	3
215	Targeting MTHFD2 in Acute Myeloid Leukemia. <i>Blood</i> , 2015 , 126, 443-443	2.2	1
214	Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. <i>Nature Communications</i> , 2014 , 5, 3469	17.4	140
213	Using glow stick chemistry for biological imaging. <i>Molecular Imaging and Biology</i> , 2014 , 16, 478-87	3.8	5
212	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014 , 46, 364-70	36.3	263
211	Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. <i>Clinical Cancer Research</i> , 2014 , 20, 1204-1211	12.9	49
210	Clinical Implementation of Genomic Sequencing in Pediatric Oncology: Identification and Valuation of Resources and Costs Associated with Next-Generation Sequencing. <i>Value in Health</i> , 2014 , 17, A645	3.3	
209	NF- κ B directs dynamic super enhancer formation in inflammation and atherogenesis. <i>Molecular Cell</i> , 2014 , 56, 219-231	17.6	392
208	Targeted imaging of Ewing sarcoma in preclinical models using a ^{64}Cu -labeled anti-CD99 antibody. <i>Clinical Cancer Research</i> , 2014 , 20, 678-87	12.9	15

207	Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2184-93	6.1	84
206	Computational repositioning and preclinical validation of pentamidine for renal cell cancer. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 1929-1941	6.1	41
205	SYK is a critical regulator of FLT3 in acute myeloid leukemia. <i>Cancer Cell</i> , 2014 , 25, 226-42	24.3	101
204	Incidence of and Risk Factors for Cytomegalovirus (CMV), Epstein Barr Virus (EBV) and Adenovirus (ADV) Reactivation in Pediatric Recipients Post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHCT). <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, S84-S85	4.7	2
203	Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. <i>Blood</i> , 2014 , 123, 3128-38	2.2	273
202	Impact of palifermin on incidence of oral mucositis and healthcare utilization in children undergoing autologous hematopoietic stem cell transplantation for malignant diseases. <i>Pediatric Transplantation</i> , 2014 , 18, 211-6	1.8	20
201	CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. <i>Leukemia</i> , 2014 , 28, 155-65	10.7	203
200	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014 , 28, 479-90	12.6	54
199	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2014 , 25, 545-546	24.3	5
198	Newer-Generation HSP90 Inhibitors Can Overcome Ibrutinib Resistance and Suppress Proliferation in Human Mantle Cell Lymphoma in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 1686-1686	2.2	3
197	Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. <i>Oncotarget</i> , 2014 , 5, 8737-49	3.3	65
196	Selective Inhibitor of Nuclear Export (SINE), Selinexor (KPT-330), Shows Remarkable Activity Against AML Leukemia-Initiating Cells. <i>Blood</i> , 2014 , 124, 995-995	2.2	
195	Vascular endothelial growth factor C is increased in endometrium and promotes endothelial functions, vascular permeability and angiogenesis and growth of endometriosis. <i>Angiogenesis</i> , 2013 , 16, 541-51	10.6	37
194	Selective HDAC1/HDAC2 inhibitors induce neuroblastoma differentiation. <i>Chemistry and Biology</i> , 2013 , 20, 713-25		68
193	High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. <i>Cancer Research</i> , 2013 , 73, 2873-83	10.1	36
192	Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2013 , 24, 777-90	24.3	491
191	A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. <i>Cancer Cell</i> , 2013 , 24, 182-96	24.3	114
190	Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. <i>Leukemia</i> , 2013 , 27, 852-60	10.7	134

189	KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2013 , 161, 117-27	4.5	130
188	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. <i>Nature Medicine</i> , 2013 , 19, 1518-23	50.5	105
187	Oncogenic BRAF regulates oxidative metabolism via PGC1 β and MITF. <i>Cancer Cell</i> , 2013 , 23, 302-15	24.3	539
186	Complementary genomic screens identify SERCA as a therapeutic target in NOTCH1 mutated cancer. <i>Cancer Cell</i> , 2013 , 23, 390-405	24.3	97
185	Shikonin, a natural product from the root of <i>Lithospermum erythrorhizon</i> , is a cytotoxic DNA-binding agent. <i>European Journal of Pharmaceutical Sciences</i> , 2013 , 49, 18-26	5.1	21
184	Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. <i>Cancer Discovery</i> , 2013 , 3, 870-9	24.4	93
183	Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. <i>Clinical Cancer Research</i> , 2013 , 19, 6183-92	12.9	150
182	Targeting MYCN in neuroblastoma by BET bromodomain inhibition. <i>Cancer Discovery</i> , 2013 , 3, 308-23	24.4	460
181	Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. <i>Leukemia</i> , 2013 , 27, 66-74	10.7	141
180	AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/Eatenin signaling pathway. <i>Blood</i> , 2013 , 121, 4906-16	2.2	43
179	In vivo imaging method to distinguish acute and chronic inflammation. <i>Journal of Visualized Experiments</i> , 2013 ,	1.6	14
178	Differential disruption of EWS-FLI1 binding by DNA-binding agents. <i>PLoS ONE</i> , 2013 , 8, e69714	3.7	12
177	Abstract 4622: Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. 2013 ,		2
176	New cast for a new era: preclinical cancer drug development revisited. <i>Journal of Clinical Investigation</i> , 2013 , 123, 3639-45	15.9	63
175	Potential Role Of RUNX1 In The Pathogenesis Of Juvenile Myelomonocytic Leukemia (JMML). <i>Blood</i> , 2013 , 122, 45-45	2.2	1
174	Novel Inhibitors Of CRM1/XPO1 Nuclear Exporter Exhibit Striking Activity Against AML Primarygrafts, Including AML Leukemia Initiating Cells, While Sparing Normal Hematopoietic Cells. <i>Blood</i> , 2013 , 122, 3932-3932	2.2	
173	Using Small Molecules To Identify Critical Signaling Pathways Of Mutant N-RAS In Acute Leukemia Cells. <i>Blood</i> , 2013 , 122, 169-169	2.2	
172	Targeting Oncogenic Interleukin-7 Receptor Signaling With N-Acetylcysteine In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013 , 122, 2535-2535	2.2	

171	Novel Fc-Engineered Anti-B Cell Maturation Antigen-Monomethyl Auristatin F Antibody-Drug Conjugate (GSK2857916) Induces Potent and Selective Anti-Multiple Myeloma Activity Via Enhanced Effector Function and Direct Tumor Cell Killing. <i>Blood</i> , 2013 , 122, 877-877	2.2	1
170	Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. <i>Blood</i> , 2012 , 119, 2579-89	2.2	458
169	P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. <i>Blood</i> , 2012 , 119, 1468-78	2.2	84
168	The requirement for cyclin D function in tumor maintenance. <i>Cancer Cell</i> , 2012 , 22, 438-51	24.3	234
167	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. <i>Blood</i> , 2012 , 120, 2843-52	2.2	298
166	Incongruity of imaging using fluorescent 2-DG conjugates compared to 18F-FDG in preclinical cancer models. <i>Molecular Imaging and Biology</i> , 2012 , 14, 553-60	3.8	23
165	Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2012 , 22, 359-72	24.3	148
164	In vivo imaging of inflammatory phagocytes. <i>Chemistry and Biology</i> , 2012 , 19, 1199-209		58
163	Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. <i>Leukemia</i> , 2012 , 26, 985-90	10.7	86
162	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. <i>Nature</i> , 2012 , 483, 613-7	50.4	361
161	The JAK2V617F oncogene requires expression of inducible phosphofructokinase/fructose-bisphosphatase 3 for cell growth and increased metabolic activity. <i>Leukemia</i> , 2012 , 26, 481-9	10.7	29
160	A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. <i>Journal of Clinical Investigation</i> , 2012 , 122, 2018-31	15.9	134
159	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. <i>Blood</i> , 2012 , 119, 5782-94	2.2	234
158	Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. <i>Cancer Cell</i> , 2012 , 21, 547-62	24.3	145
157	Mice heterozygous for CREB binding protein are hypersensitive to β -radiation and invariably develop myelodysplastic/myeloproliferative neoplasm. <i>Experimental Hematology</i> , 2012 , 40, 295-306.e5	3.1	25
156	The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. <i>Genes and Cancer</i> , 2012 , 3, 503-11	2.9	74
155	Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors. <i>Leukemia</i> , 2012 , 26, 2233-44	10.7	50
154	Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. <i>Nature Medicine</i> , 2012 , 18, 1118-22	50.5	136

153	Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 942-51	6.1	43
152	Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. <i>Journal of Experimental Medicine</i> , 2012 , 209, 259-73	16.6	129
151	Targeted disruption of the BCL9/Ectatenin complex inhibits oncogenic Wnt signaling. <i>Science Translational Medicine</i> , 2012 , 4, 148ra117	17.5	186
150	Anti-inflammatory properties of histone deacetylase inhibitors: a mechanistic study. <i>Journal of Trauma</i> , 2012 , 72, 347-53; discussion 353-4		23
149	The intersection of genetic and chemical genomic screens identifies GSK-3 β as a target in human acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2012 , 122, 935-47	15.9	84
148	In Vivo Fluorescent Labeling of Tumor Cells with the HaloTag \square Technology. <i>Current Chemical Genomics</i> , 2012 , 6, 48-54		11
147	Newer-Generation HSP90 Inhibitors Have Potent Activity Against Human Mantle Cell Lymphoma in Vitro and in Vivo. <i>Blood</i> , 2012 , 120, 1651-1651	2.2	
146	CRM1 Blockade by Novel Inhibitors of Nuclear Export (SINEs) Inhibits Multiple Myeloma Cell Growth, Osteoclastogenesis, and Myeloma-Induced Osteolysis. <i>Blood</i> , 2012 , 120, 326-326	2.2	
145	A Structural Basis for p53-Deficiency, Deregulated Cell Cycle and Unfavorable Outcome in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012 , 120, 1534-1534	2.2	
144	Deciphering the Critical Pathways of Mutant N-RAS in AML Using Small Molecule Inhibitors.. <i>Blood</i> , 2012 , 120, 2455-2455	2.2	
143	Aldehyde Dehydrogenase 3a2 (Aldh3a2) Represents a Distinct Metabolic Vulnerability in MLL-AF9 AML Leukemia Initiating Cells. <i>Blood</i> , 2012 , 120, 208-208	2.2	
142	BET bromodomain inhibition as a therapeutic strategy to target c-Myc. <i>Cell</i> , 2011 , 146, 904-17	56.2	2045
141	Green tea epigallocatechin-3-gallate inhibits angiogenesis and suppresses vascular endothelial growth factor C/vascular endothelial growth factor receptor 2 expression and signaling in experimental endometriosis in vivo. <i>Fertility and Sterility</i> , 2011 , 96, 1021-8	4.8	66
140	Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. <i>PLoS ONE</i> , 2011 , 6, e20226	3.7	27
139	Inactivation of a single copy of Crebbp selectively alters pre-mRNA processing in mouse hematopoietic stem cells. <i>PLoS ONE</i> , 2011 , 6, e24153	3.7	6
138	Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. <i>Blood</i> , 2011 , 118, 69-79	2.2	31
137	SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. <i>Nature</i> , 2011 , 471, 104-9	50.4	489
136	Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. <i>Cancer Cell</i> , 2011 , 20, 53-65	24.3	712

135	MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. <i>Cancer Cell</i> , 2011 , 20, 66-78	24.3	647
134	Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas. <i>Journal of Neuro-Oncology</i> , 2011 , 104, 179-89	4.8	22
133	A class of human proteins that deliver functional proteins into mammalian cells in vitro and in vivo. <i>Chemistry and Biology</i> , 2011 , 18, 833-8		80
132	Differentiation of NUT midline carcinoma by epigenomic reprogramming. <i>Cancer Research</i> , 2011 , 71, 2686-96	10.1	140
131	Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. <i>Journal of Biomedical Optics</i> , 2011 , 16, 011006	3.5	32
130	Hypoxia-induced transcriptional repression of the melanoma-associated oncogene MITF. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, E924-33	11.5	89
129	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Experimental Medicine</i> , 2011 , 208, 1809-22	16.6	133
128	A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo. <i>Neuro-Oncology</i> , 2011 , 13, 820-9	1	25
127	KPT-SINE, a Potent, Small Molecule Inhibitor of CRM1-Dependent Nuclear-Cytoplasmic Shuttling, with Potent Activity Against T-ALL and AML. <i>Blood</i> , 2011 , 118, 2622-2622	2.2	2
126	Pharmacodynamic and Pharmacokinetic Properties of a Novel and Selective HDAC6 Inhibitor, ACY-1215, in Combination with Bortezomib in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2912-2912	2.2	1
125	High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. <i>Journal of Cell Biology</i> , 2011 , 194, i8-i8	7.3	
124	Selective HDAC6 Inhibition Via ACY-1215, Either Alone or in Combination with Bortezomib, Restores Osteoblast Function and Suppresses Osteoclast Differentiation in Multiple Myeloma. <i>Blood</i> , 2011 , 118, 2908-2908	2.2	1
123	Hypoxia Promotes Dissemination of Multiple Myeloma Through Acquisition of Endothelial to Mesenchymal Transition (EMT) Features. <i>Blood</i> , 2011 , 118, 471-471	2.2	
122	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011 , 118, 1409-1409	2.2	
121	Combined Targeting of the MET and FGF Receptor Tyrosine Kinases Induces Sustained AML Cell Death by Preventing Compensatory Upregulation of HGF in Response to MET Kinase Inhibition. <i>Blood</i> , 2011 , 118, 1405-1405	2.2	1
120	Intersecting High-Throughput Screens Identifies SERCA As a Target for Modulating NOTCH1 In Hematopoietic Malignancies. <i>Blood</i> , 2011 , 118, 555-555	2.2	
119	Potentiation of the Effects of Nilotinib by Combination with Plerixafor in a Mouse Model of BCR-ABL-Positive Residual Disease. <i>Blood</i> , 2011 , 118, 2737-2737	2.2	
118	HSP90 Inhibition Targets JAK2 and Is Highly Effective in CRLF2-Rearranged Acute Lymphoblastic Leukemia. <i>Blood</i> , 2011 , 118, 576-576	2.2	

117	Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML. <i>Leukemia</i> , 2010 , 24, 1375-8	10.7	13
116	Selective inhibition of BET bromodomains. <i>Nature</i> , 2010 , 468, 1067-73	50.4	2725
115	Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. <i>Nature Medicine</i> , 2010 , 16, 483-9	50.5	247
114	Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. <i>Cancer Research</i> , 2010 , 70, 9827-36	10.1	164
113	Smac mimetics: implications for enhancement of targeted therapies in leukemia. <i>Leukemia</i> , 2010 , 24, 2100-9	10.7	81
112	Discovery and characterization of novel mutant FLT3 kinase inhibitors. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 2468-77	6.1	13
111	Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants. <i>Blood</i> , 2010 , 115, 4206-16 ²	2.2	59
110	An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. <i>Cancer Cell</i> , 2010 , 17, 298-310	24.3	183
109	A stapled p53 helix overcomes HDMX-mediated suppression of p53. <i>Cancer Cell</i> , 2010 , 18, 411-22	24.3	233
108	Selective Inhibition of HDAC1 and HDAC2 Is a Potential Therapeutic Option for B-All. <i>Blood</i> , 2010 , 116, 2900-2900	2.2	2
107	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). <i>Blood</i> , 2010 , 116, 2997-2997	2.2	1
106	Selectin Inhibition Disrupts Multiple Myeloma Cells Interaction with the Bone Marrow Microenvironment and Sensitizes Them to Therapy. <i>Blood</i> , 2010 , 116, 453-453	2.2	1
105	Dynamic Regulation of the Level of Hypoxia In the Bone Marrow Regulates Cell Dissemination In Multiple Myeloma. <i>Blood</i> , 2010 , 116, 4035-4035	2.2	
104	MLN4924, a Novel Investigational NEDD8 Activating Enzyme Inhibitor, Exhibits Preclinical Activity In Multiple Myeloma and Waldenstro m's Macroglobulinemia through Mechanism Distinct From Existing Proteasome Inhibitors. <i>Blood</i> , 2010 , 116, 2988-2988	2.2	1
103	Intersecting Chemical Genomic and Genetic Screens Identifies Glycogen Synthase Kinase-3 β (GSK-3 β) as a Modulator of Differentiation In Acute Myeloid Leukemia. <i>Blood</i> , 2010 , 116, 1000-1000	2.2	
102	Preclinical Studies of Salinomycin In Multiple Myeloma (MM) Models: Targeting of Side Population (SP) Cells In the Context of Tumor Microenvironment Interactions.. <i>Blood</i> , 2010 , 116, 1574-1574	2.2	2
101	Aberrant Expression of Hepatocyte Growth Factor Induces Autocrine MET Activation Providing a Novel Therapeutic Target In Acute Myeloid Leukemia.. <i>Blood</i> , 2010 , 116, 1042-1042	2.2	
100	Demonstration of a Role for Dot1l In MLL-Rearranged Leukemia Using a Conditional Loss of Function Model. <i>Blood</i> , 2010 , 116, 62-62	2.2	

99	CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 16275-80	11.5	122
98	Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 4260-5	11.5	316
97	The F-box protein beta-TrCp1/Fbw1a interacts with p300 to enhance beta-catenin transcriptional activity. <i>Journal of Biological Chemistry</i> , 2009 , 284, 13033-44	5.4	11
96	Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 519-32	9.7	293
95	Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. <i>Neuro-Oncology</i> , 2009 , 11, 109-21	1	89
94	Lipocalin 2 promotes breast cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009 , 106, 3913-8	11.5	245
93	Proteomic and genetic approaches identify Syk as an AML target. <i>Cancer Cell</i> , 2009 , 16, 281-94	24.3	124
92	Direct inhibition of the NOTCH transcription factor complex. <i>Nature</i> , 2009 , 462, 182-8	50.4	639
91	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. <i>Nature Biotechnology</i> , 2009 , 27, 77-83	44.5	190
90	Preferential binding of HIF-1 to transcriptionally active loci determines cell-type specific response to hypoxia. <i>Genome Biology</i> , 2009 , 10, R113	18.3	103
89	Glioblastoma inhibition by cell surface immunoglobulin protein EWI-2, in vitro and in vivo. <i>Neoplasia</i> , 2009 , 11, 77-86, 4p following 86	6.4	38
88	Desferroxamine infusion increases cerebral blood flow: a potential association with hypoxia-inducible factor-1. <i>Clinical Science</i> , 2009 , 116, 771-9	6.5	18
87	HOXA9 is required for survival in human MLL-rearranged acute leukemias. <i>Blood</i> , 2009 , 113, 2375-85	2.2	239
86	Identification of AML1-ETO modulators by chemical genomics. <i>Blood</i> , 2009 , 113, 6193-205	2.2	33
85	CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. <i>Blood</i> , 2009 , 113, 4341-51	2.2	354
84	Systematic in vivo structure-function analysis of p300 in hematopoiesis. <i>Blood</i> , 2009 , 114, 4804-12	2.2	29
83	In Vivo Pharmacodynamic Imaging of Proteasome Inhibition. <i>Molecular Imaging</i> , 2009 , 8, 7290.2009.0000077	9.7	33
82	HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2160-70	15.9	115

81	HIF2 α cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009 , 119, 3182-3182	15.9	4
80	DOT1L and Histone H3 Lysine79 Methylation as a Therapeutic Target in Mixed Lineage Leukemia.. <i>Blood</i> , 2009 , 114, 212-212	2.2	1
79	Cell of Origin Influences Leukemia Stem Cell Phenotype.. <i>Blood</i> , 2009 , 114, 3459-3459	2.2	
78	Microenvironment-Dependent Synthetic Lethality: Implications for Tumor Pathophysiology and Anti-Cancer Drug Discovery.. <i>Blood</i> , 2009 , 114, 1722-1722	2.2	
77	In vivo pharmacodynamic imaging of proteasome inhibition. <i>Molecular Imaging</i> , 2009 , 8, 140-7	3.7	32
76	MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment. <i>Leukemia</i> , 2008 , 22, 66-77	10.7	88
75	H3K79 methylation profiles define murine and human MLL-AF4 leukemias. <i>Cancer Cell</i> , 2008 , 14, 355-68	24.3	440
74	Anti-apoptosis mechanisms in malignant gliomas. <i>Journal of Clinical Oncology</i> , 2008 , 26, 493-500	2.2	82
73	Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. <i>Pigment Cell and Melanoma Research</i> , 2008 , 21, 457-63	4.5	77
72	Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 1121-9	6.1	57
71	Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. <i>Human Molecular Genetics</i> , 2008 , 17, 1774-82	5.6	41
70	Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 9751-6	11.5	71
69	Potential of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells. <i>Blood</i> , 2008 , 111, 3723-34	2.2	73
68	Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells. <i>Blood</i> , 2008 , 112, 5161-70	2.2	25
67	Therapeutic targeting of apoptosis pathways in cancer. <i>Current Opinion in Oncology</i> , 2008 , 20, 97-103	4.2	66
66	Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. <i>Journal of Clinical Investigation</i> , 2008 , 118, 3109-22	15.9	76
65	Stapled Peptides: Leveraging the BH3 Helix to Create a New Class of Drugs to Treat Hematological Malignancies. <i>Blood</i> , 2008 , 112, 2929-2929	2.2	
64	Activity of Plk Inhibitor BI2536 on Myeloma Cells. <i>Blood</i> , 2008 , 112, 2764-2764	2.2	

63	In Vivo Imaging Model of Multiple Myeloma and Its Cellular Interaction with the Bone Marrow Microenvironment. <i>Blood</i> , 2008 , 112, 647-647	2.2	
62	Potential of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1951-61	6.1	71
61	Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. <i>Blood</i> , 2007 , 109, 2708-17	2.2	373
60	Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. <i>Blood</i> , 2007 , 109, 2112-20	2.2	93
59	Practices and pitfalls of mouse cancer models in drug discovery. <i>Advances in Cancer Research</i> , 2007 , 96, 191-212	5.9	53
58	In Vivo Mobilization of Multiple Myeloma Cells Out of the Bone Marrow Using the CXCR4 Inhibitor AMD3100 and Bortezomib: Implications for Sensitization of Myeloma Cells to Apoptosis.. <i>Blood</i> , 2007 , 110, 2501-2501	2.2	3
57	Global Increase in H3K79 Dimethylation in Murine and Human MLL-AF4 Lymphoblastic Leukemias.. <i>Blood</i> , 2007 , 110, 344-344	2.2	2
56	Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. <i>PLoS Medicine</i> , 2007 , 4, e122	11.6	111
55	HOXA9 Represses Bim Expression in MLL Rearranged Leukemia: Implications for Drug Therapy.. <i>Blood</i> , 2007 , 110, 57-57	2.2	
54	The Myocyte Enhancer Factor 2C (MEF2C) Is a Direct Transcriptional Target of HOXA9 and Mediates Leukemia Survival in Human Mixed-Lineage Leukemias.. <i>Blood</i> , 2007 , 110, 58-58	2.2	1
53	Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers. <i>Cancer Cell</i> , 2006 , 9, 473-84	24.3	140
52	Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. <i>FASEB Journal</i> , 2006 , 20, 947-9	0.9	100
51	CXCR4 inhibition synergizes with cytotoxic chemotherapy in gliomas. <i>Clinical Cancer Research</i> , 2006 , 12, 6765-71	12.9	113
50	Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland. <i>Cancer Research</i> , 2006 , 66, 11381-8	10.1	44
49	A novel noninvasive model of endometriosis for monitoring the efficacy of antiangiogenic therapy. <i>American Journal of Pathology</i> , 2006 , 168, 2074-84	5.8	69
48	Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. <i>Gastroenterology</i> , 2006 , 131, 1734-42	13.3	77
47	Noninvasive bioluminescence imaging of luciferase expressing intracranial U87 xenografts: correlation with magnetic resonance imaging determined tumor volume and longitudinal use in assessing tumor growth and antiangiogenic treatment effect. <i>Neurosurgery</i> , 2006 , 58, 365-72; discussion 365-72	3.2	102
46	Antimyeloma activity of heat shock protein-90 inhibition. <i>Blood</i> , 2006 , 107, 1092-100	2.2	249

45	Induction of Bim Facilitates Apoptosis in Leukemia Cells Treated with HDAC Inhibitors.. <i>Blood</i> , 2006 , 108, 1994-1994	2.2	
44	Comprehensive In Vivo Analysis of p300 Hematopoietic Tumor Suppressor Functions.. <i>Blood</i> , 2006 , 108, 2553-2553	2.2	
43	MLL-AF9 Initiates Leukemia from a Single Committed Hematopoietic Progenitor.. <i>Blood</i> , 2006 , 108, 2534-2534		
42	HoxA9 Knockdown Inhibits Proliferation and Induces Cell Death in Human MLL-Rearranged Leukemias.. <i>Blood</i> , 2006 , 108, 734-734	2.2	
41	Harnessing the power of fireflies and mice for assessing cancer mechanisms. <i>Drug Discovery Today Disease Mechanisms</i> , 2005 , 2, 153-158		5
40	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. <i>Cancer Cell</i> , 2005 , 7, 129-133	2.4.3	1248
39	Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. <i>Cancer Cell</i> , 2005 , 7, 399-403	2.4.3	6
38	A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. <i>PLoS Genetics</i> , 2005 , 1, 72-80	6	335
37	Cyclin D1 represses p300 transactivation through a cyclin-dependent kinase-independent mechanism. <i>Journal of Biological Chemistry</i> , 2005 , 280, 29728-42	5.4	81
36	In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. <i>Cancer Research</i> , 2005 , 65, 8324-30	10.1	40
35	Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. <i>Genes and Development</i> , 2005 , 19, 489-501	12.6	987
34	Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. <i>Journal of Biological Chemistry</i> , 2005 , 280, 3996-4003	5.4	87
33	Widespread CXCR4 activation in astrocytomas revealed by phospho-CXCR4-specific antibodies. <i>Cancer Research</i> , 2005 , 65, 11392-9	10.1	88
32	PKC412 Is a Multi-Targeting Kinase Inhibitor with Activity Against Multiple Myeloma In Vitro and In Vivo.. <i>Blood</i> , 2005 , 106, 247-247	2.2	3
31	MLL-AF9 and FLT3 Cooperation during Myeloid Leukemogenesis: Development of a Model for Rapid Testing of New Therapeutics.. <i>Blood</i> , 2005 , 106, 1605-1605	2.2	
30	p53 targets simian virus 40 large T antigen for acetylation by CBP. <i>Journal of Virology</i> , 2004 , 78, 8245-53	6	48
29	Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. <i>Bone Marrow Transplantation</i> , 2004 , 34, 795-8	4.4	18
28	Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. <i>Cancer Cell</i> , 2004 , 5, 221-30	24.3	529

27	Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. <i>Cancer Cell</i> , 2004 , 6, 33-43	24.3	413
26	Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. <i>Science</i> , 2004 , 305, 1466-70	33.3	1098
25	The mTOR Inhibitor RAD001 (everolimus) Is Active Against Multiple Myeloma Cells In Vitro and in Vivo.. <i>Blood</i> , 2004 , 104, 1496-1496	2.2	5
24	AMD107: Efficacy as a Selective Inhibitor of the Tyrosine Kinase Activity of BCR-ABL in Murine Leukemia Models.. <i>Blood</i> , 2004 , 104, 551-551	2.2	2
23	A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 13513-8	11.5	537
22	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination. <i>Molecular Imaging</i> , 2003 , 2, 153535002003031	3.7	
21	Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. <i>Cancer Cell</i> , 2003 , 3, 173-83	24.3	353
20	Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. <i>Nature Structural and Molecular Biology</i> , 2003 , 10, 504-12	17.6	157
19	Polyubiquitination of p53 by a ubiquitin ligase activity of p300. <i>Science</i> , 2003 , 300, 342-4	33.3	402
18	Mouse reporter strain for noninvasive bioluminescent imaging of cells that have undergone Cre-mediated recombination. <i>Molecular Imaging</i> , 2003 , 2, 297-302	3.7	111
17	Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 5367-72	11.5	357
16	Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 14789-94	11.5	181
15	A new spectrin, beta IV, has a major truncated isoform that associates with promyelocytic leukemia protein nuclear bodies and the nuclear matrix. <i>Journal of Biological Chemistry</i> , 2001 , 276, 23974-85	5.4	51
14	Role of T-bet in commitment of TH1 cells before IL-12-dependent selection. <i>Science</i> , 2001 , 292, 1907-10	33.3	665
13	Suppression of tumor growth through disruption of hypoxia-inducible transcription. <i>Nature Medicine</i> , 2000 , 6, 1335-40	50.5	646
12	A stimulus-specific role for CREB-binding protein (CBP) in T cell receptor-activated tumor necrosis factor alpha gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000 , 97, 3925-9	11.5	52
11	p300 interacts with the nuclear proto-oncoprotein SYT as part of the active control of cell adhesion. <i>Cell</i> , 2000 , 102, 839-48	56.2	83
10	Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. <i>Genes and Development</i> , 2000 , 14, 272-7	12.6	303

9	Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. <i>Genes and Development</i> , 2000 , 14, 272-277	12.6	234
8	Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. <i>Genes and Development</i> , 1999 , 13, 64-75	12.6	304
7	p300/MDM2 complexes participate in MDM2-mediated p53 degradation. <i>Molecular Cell</i> , 1998 , 2, 405-15	17.6	351
6	Life, death and genomic change in perturbed cell cycles 1995 , 75-81		3
5	Cyclin B1 expression in HeLa S3 cells studied by flow cytometry. <i>Experimental Cell Research</i> , 1994 , 211, 275-81	4.2	52
4	In vivo inhibition of cyclin B degradation and induction of cell-cycle arrest in mammalian cells by the neutral cysteine protease inhibitor N-acetylleucylleucylnorleucinal. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 3353-7	11.5	88
3	cDNA expression cloning in human cells using the pDR2 episomal vector system. <i>Methods</i> , 1992 , 4, 111-126	12.6	18
2	Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 9553-7	11.5	200
1	Cytotoxic effects of cell cycle phase specific agents: result of cell cycle perturbation. <i>Cancer Research</i> , 1990 , 50, 7307-17	10.1	99